Detalles de la búsqueda
1.
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
J Med Virol
; 96(4): e29598, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38624044
2.
Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Clin Infect Dis
; 76(3): e629-e637, 2023 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35982541
3.
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
J Med Virol
; 95(6): e28868, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306318
4.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
Liver Int
; 43(10): 2130-2141, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37649460
5.
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Clin Infect Dis
; 75(1): e552-e563, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366316
6.
Results of an interventional HIV testing programme in the context of a mpox (formerly monkeypox) vaccination campaign in Latium Region, Italy, August to October 2022.
Euro Surveill
; 27(48)2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695459
7.
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease.
J Antimicrob Chemother
; 76(12): 3272-3279, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529797
8.
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
HIV Med
; 22(6): 519-525, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33480094
9.
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
J Med Virol
; 93(3): 1796-1804, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32975842
10.
The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review.
Int J Mol Sci
; 22(15)2021 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34360707
11.
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
J Antimicrob Chemother
; 75(1): 194-199, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605107
12.
JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
J Med Virol
; 96(5): e29631, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38682689
13.
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy.
Sex Transm Infect
; 95(8): 619-625, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31076456
14.
Liver fibrosis is associated with cognitive impairment in people living with HIV.
Infection
; 47(4): 589-593, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30784024
15.
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
BMC Infect Dis
; 19(1): 59, 2019 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-30654739
16.
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients.
New Microbiol
; 42(2): 69-80, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785209
17.
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
J Antimicrob Chemother
; 73(7): 1955-1964, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29668978
18.
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
J Antimicrob Chemother
; 72(7): 2055-2059, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28333353
19.
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects.
Pharmacol Res
; 176: 106064, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34999223
20.
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
J Antimicrob Chemother
; 71(12): 3519-3527, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27543658